Neonatal opioid withdrawal syndrome.
Neonatal opioid withdrawal syndrome is common due to the current opioid addiction epidemic. Infants born to women covertly abusing prescription opioids may not be identified as at risk until withdrawal signs present. Buprenorphine is a newer treatment for maternal opioid addiction and appears to result in a milder withdrawal syndrome than methadone. Initial treatment is with nonpharmacological measures including decreasing stimuli, however pharmacological treatment is commonly required. Opioid monotherapy is preferred, with phenobarbital or clonidine uncommonly needed as adjunctive therapy. Rooming-in and breastfeeding may decease the severity of withdrawal. Limited evidence is available regarding long-term effects of perinatal opioid exposure.
['Sutter|Mary Beth|MB|', 'Leeman|Lawrence|L|', 'Hsi|Andrew|A|']
D000701:Analgesics, Opioid D001942:Breast Feeding D002047:Buprenorphine D005260:Female D006801:Humans D007231:Infant, Newborn D008297:Male D008691:Methadone D009357:Neonatal Abstinence Syndrome D058850:Opiate Substitution Treatment D011247:Pregnancy D011248:Pregnancy Complications D011256:Pregnancy Outcome D012307:Risk Factors D019966:Substance-Related Disorders D014481:United States
Neonatal opioid withdrawal Buprenorphine Methadone Neonatal abstinence syndrome Perinatal substance abuse